Ondansetron Use in Myasthenic Crisis

Safety and Efficacy

The American College of Medical Toxicology and other medical guidelines suggest that ondansetron is safe to use in myasthenic crisis and should be administered without hesitation for the management of nausea and vomiting in these patients, with no specific contraindications or safety concerns documented for its use in patients with myastenia gravis or myasthenic crisis 1.
There is no known interaction between ondansetron and myastenia gravis that would contraindicate its use during a myasthenic crisis, according to medical guidelines 1.
Ondansetron is a 5-HT3 receptor antagonist that acts by blocking serotonin receptors in the chemoreceptor trigger zone and vagal afferents, without effects on neuromuscular transmission, as stated by the medical guidelines 2.

For adults with nausea and vomiting during myasthenic crisis, the standard dose is 4-8 mg IV or orally every 8-12 hours, with a maximum daily dose of 24 mg, as recommended by medical guidelines 1, 2.
The intramuscular route can be used, with a dose of 4-8 mg IM when IV access is not available or when there are persistent vomiting, according to medical guidelines 2.

Ondansetron should be administered while simultaneously treating the underlying myasthenic crisis with plasmapheresis or intravenous immunoglobulin, as part of a comprehensive management plan, according to medical guidelines 1.
Adequate hydration should be ensured along with antiemetic therapy, as stated by medical guidelines 1.
The QT interval should be monitored in patients with cardiac risk factors, although QT prolongation is rare, as recommended by medical guidelines 1, 3.

If ondansetron alone is insufficient, consider adding dexamethasone 12 mg IV/orally, which improves antiemetic efficacy, as suggested by medical guidelines 2, 4.
Alternatively, proclorperazina 5-10 mg every 6 hours or metoclopramida 10 mg every 6-8 hours can be added, although with caution due to extrapyramidal effects, according to medical guidelines 1.